Agenda

Accredited by

2023 Texas Lung Cancer Conference Agenda

Event Schedule

Welcome Day

Thursday, March 30, 2023

Day One

Friday, March 31, 2023

Early Stage NSCLC

9:10 AM

Optimizing Use of Neoadjuvant Immunotherapy in NSCLC

Tina Cascone, MD, PhD (MDACC)

9:25 AM

Can We Convert Unresectable to Resectable?

Brendon Stiles, MD (Montefiore)

9:40 AM

Current Role of Adjuvant Immunotherapy in NSCLC

Jessica Donington, MD (University of Chicago)

9:55 AM

Current Role of Adjuvant Targeted Therapy in NSCLC

Eric Nadler, MD (Texas Oncology)

10:10 AM

Best Practices in Unresectable NSCLC

David Spigel, MD (Sarah Canon)

10:25 AM

Q&A

10:40 AM

Close

Immunotherapy for Advanced NSCLC

11:00 AM

When is PD(L)1 Monotherapy Enough?

Shirish Gadgeel, MD (Henry Ford)

11:10 AM

Advantages of Chemo-Immunotherapy for NSCLC

Melissa Johnson, MD (Sarah Cannon)

11:20 AM

The Evolving Role of Dual Checkpoint Inhibition

Hossein Borghaei, MD (Fox Chase)

11:30 AM

Overcoming IO Resistance in NSCLC

Sheena Bhalla, MD (UTSW)

11:45 AM

Q&A

12:00 PM

Close

SCLC and Mesothelioma

1:30 PM

Predicting the Future of Limited Stage SCLC

Kristin Higgins, MD (Emory)

1:40 PM

Best Practice for Extensive Stage SCLC

Lauren Byers, MD, PhD (MDACC)

1:55 PM

Managing Relapse for Advanced SCLC

Ticiana Leal, MD (Emory)

2:05 PM

Current Standards in Mesothelioma

Melina Marmarelis, MD (UPenn)

2:15 PM

Q&A

2:30 PM

Close

Digital Oncology

2:50 PM

Telehealth and Oncology: Natural Fit or Arranged Marriage?

Jack West, MD (COH)

3:05 PM

Remote Tobacco Cessation

Randi Williams, PhD, MPH (Georgetown)

3:20 PM

Mathematical Oncology

Alexander Anderson, MD (Moffitt)

3:35 PM

The Future of Social Media and Oncology

Narjust Florez (Duma), MD (DFCI)

3:50 PM

Q&A

4:05 PM

Close

4:05 PM - 4:50 PM

Surprise Guest Speaker

Day Two

Saturday, April 1, 2023

Targeted Therapy: EGFR, HER2

9:10 AM

Biomarkers: What is NGS?

Christine Lovly, MD, PhD (Vanderbilt)

9:25 AM

First Line EGFR NSCLC: Is TKI enough?

Sandip Patel, MD (UCSD)

9:35 AM

Emerging Strategies for EGFR Exon 20

Julia Rotow, MD (DFCI)

9:50 AM

Overcoming EGFR TKI Resistance

Jonathan Reiss, MD, (UC Davis)

10:05 AM

Targeting HER2 in NSCLC

Estelamari Rodriguez, MD (University of Miami)

10:15 AM

Refining EGFR Classification

John Heymach, MD, PhD (MDACC)

10:25 AM

Q&A

10:40 AM

Close

Targeted Therapy: Mutations: KRAS/BRAF/MET and ADCs

11:00 AM

Treating KRAS Mutant NSCLC

Ferdinandos Skoulidis, MD (MDACC)

11:15 AM

Best Practice for BRAF Mutant NSCLC

Ibiayi Dagogo-Jack, MD (MGH)

11:25 AM

Current and Future Practice for METex14

Paul Paik, MD (MSKCC)

11:35 AM

Placing ADCs in the Treatment Algorithm

Joshua Reuss, MD (Georgetown)

11:45 AM

Q&A

12:00 PM

Close

Targeted Therapy: Fusions

1:30 PM

First Line Options for ALK and ROS1 NSCLC

Jason Porter, MD (West)

1:40 PM

Understanding and Overcoming Resistance in ALK/ROS1 NSCLC

Jessica Lin, MD, (MGH)

1:55 PM

Targeted Therapy for RET NSCLC

Edgardo Santos, MD (Genesis)

2:05 PM

NTRK and NRG1 in NSCLC

Yasir Elamin, MD (MDACC)

2:15 PM

Q&A

2:30PM

Close

Refining Practice for the Coming Year

2:50 PM

Intersection of Community and Academic Oncology

R. Steven Paulson, MD (Texas Oncology)

3:00 PM

How to Incorporate Liquid Biopsy in Practice

Luis Raez, MD (Memorial Miami)

3:10 PM

Health Care Policy for Today's Oncologist

Debra Patt, MD, PhD (Texas Oncology)

3:20 PM

Debate Introduction: Is There A Role For CTLA-4 In MNSCLC

Keunchil Park, MD (MDACC)

3:20 PM

Debate: Is there a role for CTLA-4 in mNSCLC (FOR)

Balazs Halmos, MD (Montefiore)

3:30 PM

Debate: Is there a role for CTLA-4 in mNSCLC (AGAINST)

Ben Levy, MD (Johns Hopkins)

3:40 PM

Q&A

4:00 PM

Close

7:00 PM

Farewell Reception

Experience Austin, Texas

Come for the education.

We look forward to hosting a unique conference at the historic venue, ACL Live at the Moody Theater in Austin, Texas. REGISTER NOW!